Cancer

FDA grants priority review to Enhertu for breast cancer subset – Healio

The FDA granted priority review to fam-trastuzumab deruxtecan-nxki for treatment of certain patients with advanced breast cancer.

Read more

Show More

Related Articles

Back to top button